Postmenopausal hormone therapy - Does it cause incontinence?
Postmenopausal hormone therapy - Does it cause incontinence?
复制标题
DOI：
10.1097/01.aog.0000180394.08406.15
复制
发表时间：
2005-11-01
影响因子：
7.2
通讯作者：
Brown, JS
中科院分区：
文献类型：
--
作者：
Steinauer, JE;Waetjen, LE;Brown, JS
目的：估计激素治疗对压力和急迫性尿失禁的风险的影响。方法：心脏雌激素/孕酮替代研究是一项随机、安慰剂对照、双盲试验，旨在评估每日口服结合雌激素（0.625 mg）加醋酸甲羟孕酮（2.5 mg）治疗对已确诊心脏病的女性心脏病事件的预防作用。结果：在4.2年的治疗中，64%的随机分配到激素治疗组的妇女报告每周尿失禁，而49%的分配到安慰剂组的妇女报告每周尿失禁（P
OBJECTIVE: To estimate the effect of hormone therapy on risk of stress and urge urinary incontinence.METHODS: The Heart Estrogen/progestin Replacement Study was a randomized, placebo-controlled, double-blinded trial to evaluate daily oral conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) therapy for the prevention of heart disease events in women with established heart disease. The 1,208 participants in Heart Estrogen/progestin Replacement Study who reported no loss of urine in the previous 7 days at baseline are included in this analysis.RESULTS: During 4.2 years of treatment, 64% of women randomly assigned to hormone therapy compared with 49% of those assigned to placebo reported weekly incontinence (P